Journal of International Oncology››2024,Vol. 51››Issue (4): 254-256.doi:10.3760/cma.j.cn371439-20230908-00043
Received:2023-09-08Revised:2023-12-11Online:2024-04-08Published:2024-05-10
| [1] | Ayodele O, Razak ARA. Immunotherapy in soft-tissue sarcoma[J].Curr Oncol,2020,27: 17-23. DOI:10.3747/co.27.5407. pmid:32174754 |
| [2] | Thway K. What's new in adipocytic neoplasia?[J].Histopathology,2022,80(1): 76-97. DOI:10.1111/his.14548. pmid:34958506 |
| [3] | Sbaraglia M, Bellan E, Dei Tos AP. The 2020 WHO classification of soft tissue tumours: news and perspectives[J].Pathologica,2021,113(2): 70-84. DOI:10.32074/1591-951X-213. pmid:33179614 |
| [4] | Lee ATJ, Thway K, Huang PH, et al. Clinical and molecular spectrum of liposarcoma[J].J Clin Oncol,2018,36(2): 151-159. DOI:10.1200/JCO.2017.74.9598. pmid:29220294 |
| [5] | Zaidi MY, Canter R, Cardona K. Post-operative surveillance in retroperitoneal soft tissue sarcoma: the importance of tumor histology in guiding strategy[J].J Surg Oncol,2018,117(1): 99-104. DOI:10.1002/jso.24927. pmid:29193081 |
| [6] | Gahvari Z, Parkes A. Dedifferentiated liposarcoma: systemic therapy options[J].Curr Treat Options Oncol,2020,21(2): 15. DOI:10. 1007/s11864-020-0705-7. |
| [7] | Bourcier K, Le Cesne A, Tselikas L, et al. Basic knowledge in soft tissue sarcoma[J].Cardiovasc Intervent Radiol,2019,42(9): 1255-1261. DOI:10.1007/s00270-019-02259-w. pmid:31236647 |
| [8] | Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J].J Hematol Oncol,2018,11(1): 120. DOI:10.1186/s13045-018-0664-7. |
| [9] | Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J].Clin Cancer Res,2018,24(21): 5233-5238. DOI:10.1158/1078-0432.CCR-17-3766. pmid:29895706 |
| [10] | Zhang RS, Liu J, Deng YT, et al. The real-world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post-ALTER0203 trial era[J].Cancer Med,2022,11(11): 2271-2283. DOI:10.1002/cam4.4613. |
| [11] | Chi Y, Yao Y, Fang Z, et al. Evaluation of thyroid-stimulating hormone-increased, hypertriglyceridemia and proteinuria as markers of anlotinib efficacy in advanced soft tissue sarcoma[J].J Clin Oncol,2020,38(15_suppl): e23548. DOI:10.1200/JCO.2020.38.15_suppl.e23548. |
| [12] | Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial[J].Lancet Oncol,2019,20(6): 837-848. DOI:10.1016/S1470-2045(19)30153-6. pmid:31078463 |
| [13] | Keung EZ, Burgess M, Salazar R, et al. Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab[J].Clin Cancer Res,2020,26(6): 1258-1266. DOI:10.1158/1078-0432.CCR-19-1824. pmid:31900276 |
| [14] | Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma[J].Nature,2020,577(7791): 556-560. DOI:10.1038/s41586-019-1906-8. |
| [15] | Sun X, Xu J, Xie L, et al. Effectiveness and tolerability of anlotinib plus PD-1 inhibitors for patients with previously treated metastatic soft-tissue sarcoma[J].Int J Gen Med,2022,15: 7581-7591. DOI:10.2147/IJGM.S379269. pmid:36196372 |
| [16] | Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity[J].Annu Rev Immunol,2008,26: 677-704. DOI:10.1146/annurev.immunol.26.021607.090331. pmid:18173375 |
| [17] | Gronchi A. Surgery in soft tissue sarcoma: the thin line between a surgical or more conservative approach[J].Future Oncol,2021,17(21s): 3-6. DOI:10.2217/fon-2021-0449. pmid:34107729 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
